(This work was presented in part at the 18th Annual Meeting of the Surgical Infection Society, 30 April to 2 May 1998, abstr. P18, p. 93.
|
|
- Audra Bradford
- 6 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p Vol. 44, No /00/$ Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Nontraditional Antimicrobials against Multiresistant Acinetobacter baumannii Strains Isolated in an Intensive Care Unit Outbreak MARIA D. APPLEMAN, 1 * HOWARD BELZBERG, 2 DIANE M. CITRON, 1 PETER N. R. HESELTINE, 3 ALBERT E. YELLIN, 2 JAMES MURRAY, 2 AND THOMAS V. BERNE 2 Departments of Pathology, 1 Surgery, 2 and Medicine, 3 Los Angeles County-University of Southern California Medical Center, Los Angeles, California Received 11 January 1999/Returned for modification 29 April 1999/Accepted 13 December 1999 Fifteen multiresistant Acinetobacter baumannii isolates from patients in intensive care units and 14 nonoutbreak strains were tested to determine in vitro activities of nontraditional antimicrobials, including cefepime, meropenem, netilmicin, azithromycin, doxycycline, rifampin, sulbactam, and trovafloxacin. The latter five drugs were further tested against four of the strains for bactericidal or bacteriostatic activity by performing kill-curve studies at 0.5, 1, 2, and 4 times their MICs. In addition, novel combinations of drugs with sulbactam were examined for synergistic interactions by using a checkerboard configuration. MICs at which 90% of the isolates tested were inhibited for antimicrobials showing activity against the multiresistant A. baumannii strains were as follows (in parentheses): doxycycline (1 g/ml), azithromycin (4 g/ml), netilmicin (1 g/ml), rifampin (8 g/ml), polymyxin (0.8 U/ml), meropenem (4 g/ml), trovafloxacin (4 g/ml), and sulbactam (8 g/ml). In the kill-curve studies, azithromycin and rifampin were rapidly bactericidal while sulbactam was more slowly bactericidal. Trovafloxacin and doxycycline were bacteriostatic. None of the antimicrobials tested were bactericidal against all strains tested. The synergy studies demonstrated that the combinations of sulbactam with azithromycin, rifampin, doxycycline, or trovafloxacin were generally additive or indifferent. Acinetobacter baumannii is an aerobic, gram-negative, oxidase-negative, nonfermenting bacterium that has become an increasingly frequent cause of nosocomial infections, particularly in intensive care units (3, 4, 8, 11). It has a propensity to develop antibiotic resistance extremely rapidly (2). Successive surveys have shown increasing resistance in clinical isolates, and high proportions of strains have become resistant to older, commonly used antibiotics (6, 10, 15). Only newer antibiotics, such as broad-spectrum cephalosporins, imipenem, tobramycin, amikacin, and fluoroquinolones, remain useful. The recent development of more universally resistant strains of A. baumannii has made the search for effective therapies more important and urgent (9, 13, 14; M. Wolff, M. L. Joly-Gillou, R. Farionotti, and C. Carbon, Abstr. 37th Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-8, 1997). From 1996 through 1997, an outbreak of resistant A. baumannii infections involving 96 patients occurred in the intensive care units (ICUs) of Los Angeles County-University of Southern California (LAC-USC) Medical Center. The hospital clinical laboratory did routine susceptibility testing and reported that the isolates were resistant to imipenem, ceftazidime, cefotaxime, gentamicin, tobramycin, piperacillin-tazobactam, ticarcillin-clavulanate, ciprofloxacin, ofloxacin, and trimethoprim-sulfamethoxazole. The strains were moderately susceptible to ampicillin-sulbactam. Some strains were resistant to amikacin, and others were not. There was variability in susceptibility to amikacin among the strains, even among the same-patient strains, when testing was done by the clinical laboratory using an automated instrument. The amikacin susceptibility tests were repeated by using a reference method. * Corresponding author. Mailing address: Los Angeles County-University of Southern California Medical Center, 1200 N. State St., Room 2014, Los Angeles, CA Phone: (323) Fax: (323) mapplema@hsc.usc.edu. Since the traditional antibiotics used against gram-negative aerobic bacteria were not effective against the Acinetobacter isolates, we selected nontraditional antibiotics for potential use in eradicating these bacteria in cases where they were clinical pathogens. We determined bactericidal or bacteriostatic activities of the novel antibiotics by performing kill-curve studies on selected strains. In addition, we examined new combinations of drugs with a checkerboard configuration by looking for synergistic interactions. (This work was presented in part at the 18th Annual Meeting of the Surgical Infection Society, 30 April to 2 May 1998, abstr. P18, p. 93.) MATERIALS AND METHODS The A. baumannii strains were isolated from specimens obtained from patients in the ICUs at LAC-USC Medical Center. The specimens were processed by the clinical laboratory according to standard methods described in the Manual of Clinical Microbiology (7). Identification to genus and species levels and the original susceptibility tests were done with the Vitek automatic instrument (biomerieux Vitek, Inc., Hazelwood Mo.). The outbreak strains were sent to a reference laboratory for typing by pulse gel electrophoresis (PGE). The medical records of patients from whom one of these outbreak strains was isolated were reviewed. Fifteen of the A. baumannii isolates that were found to be multidrug resistant by the hospital clinical laboratory and 14 strains randomly selected were sent to the research laboratory and were tested for additional antibiotic susceptibilities by the agar dilution technique. Three of the outbreak strains plus one multiresistant, nonoutbreak strain were selected for kill-curve studies and synergy studies. Agar dilution test. Antibiotic laboratory standard powders of azithromycin, sulbactam, ampicillin, doxycycline, trovafloxacin (Pfizer, Inc., Groton, Conn.), cefepime, amikacin (Bristol-Myers Squibb, Princeton, N.J.), meropenem (Zeneca Pharmaceuticals, Wilmington, Del.), erythromycin (Eli Lilly, Indianapolis, Ind.), minocycline, tetracycline (Wyeth Laboratories, Philadelphia, Pa.), ciprofloxacin (Bayer Pharmaceuticals, West Haven, Conn.), netilmicin, gentamicin, isepamicin (Schering-Plough, Kenilworth, N.J.), rifampin (Novartis Pharmaceuticals, East Hanover, N.J.), and polymyxin B (Sigma Chemicals, St. Louis, Mo.) were obtained from their respective manufacturers and reconstituted according to their instructions. Stock solutions were stored at 70 C. On the day of the test, serial twofold dilutions were prepared and added to molten Mueller-Hinton agar 1035
2 1036 APPLEMAN ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 1. Specimen sources of outbreak strains of A. baumannii Source of positive specimen a Total no. of patients (%) SICU b No. of patients in: Burn ICU Respiratory tract 69 (71) Wound 36 (37) Blood 27 (28) Urine 9 (9) 6 3 Catheter tip 8 (8) 1 8 Total no. of patients a Some patients had more than one source from which A. baumannii was isolated. b Patients in all ICUs except burn ICU. for preparation of plates. Ampicillin plus sulbactam were tested together in a 2:1 ratio and separately. The organisms were incubated overnight on blood agar at 35 C. Inocula were prepared by suspending cell paste in saline to equal the turbidity of a 0.5 McFarland standard. A 1:10 dilution was prepared prior to pipetting into a Steers replicating device. The organisms were applied to the plates at a final concentration of to CFU/spot. Plates without antibiotics were inoculated before and after each set of drug-containing plates as growth controls. After overnight incubation at 35 C, the MICs were interpreted. Fifteen outbreak strains and 14 randomly selected, nonoutbreak strains were tested by agar dilution. Escherichia coli ATCC and Pseudomonas aeruginosa ATCC were included as controls. The susceptibility results for most drugs were interpreted according to National Committee for Clinical Laboratory Standards standards (12). Results for polymyxin B were interpreted according to the third edition of the Manual of Clinical Microbiology (1). Trovafloxacin results were interpreted by guidelines provided by the manufacturer. Kill curves. Four strains were selected for further studies. Three were outbreak strains isolated over a period of 2 months, each from patients in different ICUs. Strain was isolated from a blood culture from a patient in the surgical ICU; was from a blood culture in a patient in the burn ICU; and was from a sputum specimen from a medical ICU patient. The three strains were from patients in different environments who had been subjected to different antibiotic therapies and selective pressures. The fourth strain (12676) was a randomly selected blood culture isolate that exhibited a different susceptibility pattern from the pattern of the outbreak strains (susceptible to imipenem and resistant to azithromycin). Tests were performed in flasks containing 100 ml of Mueller-Hinton broth and Antimicrobial agent(s) either azithromycin, rifampin, sulbactam, trovafloxacin, or doxycycline at concentrations of 0.5, 1, 2, and 4 times the MIC for each organism. Starting inocula were to CFU/ml. The prewarmed broths were placed on an orbital shaker at 100 rpm and incubated at 35 C. Aliquots were removed after 2, 4, 8, 24, and 48 h and 7 days. The aliquots were diluted and plated quantitatively onto Mueller-Hinton agar. After overnight incubation, colonies were counted. Organisms that persisted after 48 h and 7 days were subcultured, and MICs were determined by using the agar dilution method, as described above. Synergy studies. The checkerboard method (5) was used to assess the activity of the antimicrobial combinations. Test tubes containing sulbactam plus azithromycin, doxycycline, trovafloxacin, or rifampin in 1 ml of Mueller-Hinton broth were prepared in a checkerboard configuration. The test strains were added at a final concentration of approximately 10 5 CFU/ml. After overnight incubations, the MICs were interpreted. Tubes showing no growth were subcultured onto Mueller-Hinton agar to determine the minimal bactericidal concentration. The fractional inhibitory concentration index (FIC index) for each drug was derived by dividing the concentration of that drug necessary to inhibit growth in a given row by the MIC of the drug alone for the test organism (5). The FIC index was then calculated by summing the separate FICs for each of the drugs present in that tube. Synergism was defined as an FIC index of 0.5; additivity was an FIC index of 1.0; indifference was an FIC index of 1.0 and 4; and antagonism was an FIC index of 4.0. RESULTS There are 14 medical and 40 surgical ICU beds for adult patients at the LAC-USC Medical Center. The surgical beds include those in the general surgical, neurosurgical, and burn services. Ninety-six patients who had been in one of these ICUs had at least one specimen from which multiresistant A. baumannii was isolated. In Table 1, the specimen sources of the isolates are listed. The most frequent source of the isolate was the respiratory tract, with 41% of the patients having this as their only source of positive specimen. Wound and blood specimens accounted for 37 and 28% of specimen sources, respectively. PGE patterns of the outbreak strains showed the presence of one clone with eight subtypes based on a difference of one to three minor bands. In the burn surgical ICU, there were 29 patients with A. baumannii infections. However, in this service, only one patient had the respiratory tract as the sole source of the organism. The majority, 96%, had more than one specimen site TABLE 2. In vitro activities of 18 antimicrobial agents against outbreak and randomly selected strains of A. baumannii MICs of antimicrobial agents for: Outbreak strains (n 15) a Random strains (n 14) Range 50% 90% Range 50% 90% Ampicillin-sulbactam b Sulbactam Ampicillin Cefepime Meropenem Azithromycin Erythromycin Doxycycline Minocycline Tetracycline Trovafloxacin Ciprofloxacin Netilmicin Gentamicin Amikacin Isepamicin Polymyxin B c Rifampin a These strains were resistant to imipenem, ceftazidime, cefotaxime, gentamicin, tobramycin, piperacillin-tazobactam, ticarcillin-clavulanate, ciprofloxacin, ofloxacin, and trimethoprim-sulfamethoxazole. b Ampicillin-sulbactam were tested in a ratio of 2:1. c Data are expressed in units per milliliter.
3 VOL. 44, 2000 NONTRADITIONAL AGENTS AGAINST RESISTANT ACINETOBACTER 1037 FIG. 1. The activity of trovafloxacin against strain typifies all four strains. While a slight decrease in CFU per milliliter was noted after 8 h, the drug was essentially bacteriostatic after 24 to 48 h. positive for the resistant bacteria. Twenty-one (72%) and 16 (55%) had positive wound and blood specimens, respectively. In Table 2, the determinations of the MICs at which 50 and 90% of the isolates tested were inhibited (MIC 50 s and MIC 90 s) for 18 antimicrobials are listed for the outbreak strains and for the randomly selected strains. The outbreak strains of A. baumannii were resistant to ampicillin, cefepime, erythromycin, tetracycline, ciprofloxacin, and gentamicin. However, not all the strains were resistant to amikacin, with a MIC range between 8 and 32 g/ml. The randomly selected nonoutbreak strains of Acinetobacter were resistant to ampicillin, erythromycin, tetracycline, ciprofloxacin, and gentamicin, just as the outbreak strains were. However, there were differences. Some of the randomly selected strains were resistant to azithromycin, netilmicin, and amikacin while the outbreak strains were not. Both groups of strains were susceptible to ampicillin-sulbactam, sulbactam alone at 16 g/ml, meropenem, doxycycline, minocycline, and polymyxin B and were moderately susceptible to trovafloxacin. Ampicillin alone was not active. The nonoutbreak stains were also susceptible to cefepime in this study, and many of them were susceptible to other cephalosporins and imipenem, as determined in the hospital laboratory. In the kill-curve studies, trovafloxacin showed some decrease in the number of organisms initially during the first 8 h (Fig. 1). However, after 24 h, the drug was essentially bacteriostatic. The same effect was seen with doxycycline, with an initial drop in numbers of organisms in the first 8 h of incubation followed by a subsequent static effect for the outbreak strains while having a bactericidal effect after 24 h on the nonoutbreak strain (Fig. 2). There were 28 kill-curve broths from which persistent colonies were grown when subcultured after 48 h and 7 days of exposure to the antibiotics. Two of the strains that survived after 1 week of exposure to trovafloxacin at one-half the MIC showed a twofold dilution increase in trovafloxacin MICs. The MICs of all antibiotics for the remaining 26 cultures were within 1 dilution of the MICs of the unexposed strains. MICs FIG. 2. The activity of doxycycline against strain typifies three of the strains. A slight decrease in CFU/milliliter was noted after 4 to 8 h, but regrowth started after 24 h, and the drug was essentially bacteriostatic. Strain was different in that doxycycline exerted a bactericidal effect after 24 h.
4 1038 APPLEMAN ET AL. ANTIMICROB. AGENTS CHEMOTHER. FIG. 3. Rifampin showed rapid bactericidal activity against two of the outbreak isolates: strains and for none of the strains exposed to doxycycline were more than 1 dilution different from those for the preexposed strains. Rifampin did not have consistent effects on all four strains tested. It showed rapid bactericidal activity against two of the outbreak strains (Fig. 3). Bacteriostatic effects were detected on the nonoutbreak strain and one outbreak strain (Fig. 4). Sulbactam had bactericidal effects only initially against all strains tested. After 48 h, there was regrowth (Fig. 5). MICs of sulbactam for 25 of the 28 regrowth strains were within 1 dilution of those for the preexposed strains. The MIC for one strain was 4 dilutions higher, one was 2 dilutions higher, and one was 2 dilutions lower. Azithromycin tested as bactericidal on the outbreak strains that were susceptible to the antibiotic (Fig. 6). On the nonoutbreak strain, which was resistant to azithromycin (MIC, 32 g/ml) the effect was bacteriostatic. MICs for 27 of the 28 persistent isolates were within 1 dilution of those for the preexposure strains. The MIC for one strain was 2 dilutions higher after 1 week of incubation at two times the MIC. The results of the checkerboard synergy testing are in Table 3. Using the checkerboard combinations of azithromycin, rifampin, trovafloxacin, or doxycycline with sulbactam, only the combinations of azithromycin with sulbactam and rifampin with sulbactam showed a synergistic effect with the nonoutbreak strain. The other combinations resulted in additive or indifferent effects. DISCUSSION Of all the species in the genus, A. baumannii is the main species associated with outbreaks of nosocomial infection. In recent years, the species has emerged as particularly important in nosocomial infections in ICUs, probably related to the increasingly invasive diagnostic procedures used and the increasingly greater quantity of broad-spectrum antimicrobials used. In our institution, 40 of the 96 patients from whom a resistant Acinetobacter organism was isolated had the organism in a single site. It can be argued that these patients may have been colonized as opposed to infected. The other 56 patients had more than a respiratory source positive for the organism. The FIG. 4. Rifampin was bacteriostatic against the nonoutbreak strain and the outbreak strain The third outbreak strain was resistant to rifampin (MIC 128 g/ml).
5 VOL. 44, 2000 NONTRADITIONAL AGENTS AGAINST RESISTANT ACINETOBACTER 1039 FIG. 5. The activity of sulbactam against strain typifies its activity against all the strains. There was initial bactericidal activity after 4 to 24 h, with regrowth occurring at 48 h. patients with A. baumannii isolated from a wound, blood, or urine source can be described as infected with that pathogen. The 15 strains included in this study were isolated during the first 3 months of the outbreak that occurred throughout all the ICUs. Although their antibiograms showed some variation among them, the PGE demonstrated them to belong to a single clone with eight subgroups. The control strains were of different PGE types and had different antibiograms. The striking characteristic of the outbreak strains was their resistance to imipenem as opposed to the imipenem-susceptible control strains. In the early 1970s, nosocomial Acinetobacter infections were treated successfully with gentamicin, ampicillin, naladixic acid, or carbenicillin either as single agents or in combinations (2). Successive surveys have demonstrated increasing resistance. The survey presented in this study reports an Acinetobacter organism resistant to most antibiotics, with few therapeutic choices remaining. The outbreak strains tested in this survey were resistant to erythromycin and sensitive to azithromycin. Nonoutbreak strains showed resistance to erythromycin and variable susceptibility to azithromycin. In the kill-curve studies, azithromycin, with a MIC of 4 g/ml, demonstrated rapid bactericidal activity for most strains and, with a MIC of 32 g/ml, demonstrated a bacteriostatic effect on one strain. However, the potential activity of azithromycin may not be predicted by comparing MICs to levels in serum since the drug is concentrated within the intracellular and interstitial compartments of tissues (13, 14). The extravascular MICs may be a better measure of the potential use of this drug since levels in tissue can be much higher than levels in serum according to pharmacokinetics studies. Neu has suggested that achievable tissue levels be used as breakpoints for susceptibility. Ultimately, the susceptibility breakpoints will be established by clinical studies. In the synergy results presented in this study, synergy was seen with azithromycin plus sulbactam, with a MIC of 32 g/ml for one strain. Trovafloxacin was moderately active against multiresistant A. baumannii. It had much better activity against both the outbreak and nonoutbreak strains than ciprofloxacin tested by FIG. 6. Azithromycin was bactericidal against strain and the other outbreak strains after 8 to 24 h. Azithromycin was not as active against the nonoutbreak strain (MIC 32 g/ml) and was very slowly bactericidal after 48 h and 7 days.
6 1040 APPLEMAN ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 3. Antimicrobial combination studies on multiresistant A. baumannii Strain Antibiotic combination FIC index Interpretation Rifampin sulbactam 0.31 Synergy Azithromycin sulbactam 0.38 Synergy Trovafloxacin sulbactam 0.75 Additive Doxycycline sulbactam 1.5 Indifferent Rifampin sulbactam 1.5 Indifferent Azithromycin sulbactam 2 Indifferent Trovafloxacin sulbactam 1.5 Indifferent Doxycycline sulbactam 2 Indifferent Rifampin sulbactam ND a Azithromycin sulbactam 1 Additive Trovafloxacin sulbactam 0.75 Additive Doxycycline sulbactam 2 Indifferent Rifampin sulbactam 0.75 Additive Azithromycin sulbactam 1 Additive Trovafloxacin sulbactam 1 Additive Doxycycline sulbactam 2 Indifferent a ND, not determined (because the rifampin MIC was 128 g/ml). agar dilution and ofloxacin tested with the Vitek instrument. The drug was bacteriostatic. Synergy studies with trovafloxacin and sulbactam demonstrated additive effects. Rifampin has been reported to have a strong in vitro bactericidal effect and a synergistic effect with beta-lactamase inhibitors on multiresistant A. baumannii (Wolff et al., 37th ICAAC). In our study, rifampin did not have a bactericidal effect on all strains tested and had a synergistic effect only on the nonoutbreak strain. Doxycycline, minocycline, and tetracycline were tested. Tetracycline was found to be ineffective while the other two were active. Further studies were done with doxycycline because it would be a nontoxic, inexpensive agent to use. Doxycycline had a bacteriostatic effect against three of the four outbreak strains tested. No effect was seen by combining doxycycline with sulbactam. Of the aminoglycosides tested, gentamicin, tobramycin, amikacin, and netilmicin, only netilmicin was effective against all the outbreak strains. There were several outbreak and nonoutbreak strains that demonstrated resistance to amikacin. Although the outbreak strains had MICs that are defined as amikacin susceptible, the MICs determined by agar dilution were high at 8 to 32 g/ml. The MICs determined by the automated instrument were variable for the same patient isolates. All three types of aminoglycoside-modifying enzymes have been identified within clinical Acinetobacter strains (15). In the kill-curve studies, short-term exposure of the Acinetobacter isolates to the antibiotics for 7 days or less did not result in any significant increases in resistance. The increasing antimicrobial resistance of A. baumannii presents a tremendous challenge. It is important to continue to test all potential drugs, alone or in combination, to find ways of treating the serious infections that this organism can cause. ACKNOWLEDGMENTS This study was supported by a grant from Pfizer Inc. We thank Richard Kwok and Naomi Fiorentino for excellent technical assistance. REFERENCES 1. Barry, A. L., and C. Thornberry Susceptibility testing: diffusion test procedures, p In E. H. Lennette, A. Balows, and J. P. Truant (ed.), Manual of clinical microbiology, 3rd ed. American Society for Microbiology, Washington, D.C. 2. Bergogne-Berezin, E., and K. J. Towner Acinetobacter spp. as nosocomial pathogens: microbiological, clinical and epidemiological features. Clin. Microbiol. Rev. 9: Cisneros, J. M., M. J. Reyes, J. Pachon, B. Becerril, F. J. Caballero, J. L. Garcia-Garmendia, C. Ortiz, and A. R. Cobacho Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin. Infect. Dis. 22: Corbella, X., M. Pujor, J. Ayats, M. Sendra, C. Ardanuy, M. A. Dominguez, J. Linares, J. Ariza, and F. Gudiol Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin. Infect. Dis. 23: Eliopoulos, G. M., and R. C. Moellering, Jr Antimicrobial combinations, p In V. Loria (ed.), Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, Md. 6. Go, E. S., C. Urban, J. Burns, B. Kreiswirth, W. Eisner, N. Mariano, K. M. Osinka-Snipas, and J. J. Rahal Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344: Graevenitz, A. V Acinetobacter, Alcaligenes, Moraxella, and other nonfermentative gram-negative bacteria, p In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology. American Society for Microbiology, Washington, D.C. 8. Horrevorts, A., K. Bergman, L. Kollee, I. Breuker, I. Tjernberg, and L. Dijkshoorn Clinical and epidemiological investigations of Acinetobacter genomospecies 3 in a neonatal intensive care unit. J. Clin. Microbiol. 33: Joly-Gillou, M. L., D. Decre, J. L. Herrman, E. Bourdelier, and E. Bergogne- Berezin Bactericidal in-vitro activity of -lactams and -lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. J. Antimicrob. Chemother. 36: Kuah, B. G., G. Kumarasinghe, J. Darrein, and H. R. Chang Antimicrobial susceptibilities of clinical isolates of Acinetobacter baumannii from Singapore. Antimicrob. Agents Chemother. 38: Lortholary, O., J. Y. Fagon, A. B. Hoi, M. A. Slama, J. Pierre, P. Giral, R. Rosenzweig, L. Gutmann, M. Safar, and J. Acar Nosocomial acquisition of Acinetobacter baumannii: risk factors and prognosis. Clin. Infect. Dis. 20: National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing, seventh informational supplement. M100-S7, vol. 17, no. 2. National Committee for Clinical Laboratory Standards, Wayne, Pa. 13. Neu, H. C Clinical microbiology of azithromycin. Am. J. Med. 91(3A): 12S 18S. 14. Schentag, J. J., and C. H. Ballow Tissue-directed pharmacokinetics. Am. J. Med. 91(3A):5S 11S. 15. Traub, W. H., and M. Spohr Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3 and genospecies 6). Antimicrob. Agents Chemother. 33:
a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationIN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA
IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA YONGYUTH JITTAROPAS NAOTO 1), RIKITOMI 2), and Kaizo MATSUMOTO 2) 1) Department of
More informationEvaluation of the AutoMicrobic System for Susceptibility Testing of Aminoglycosides and Gram-Negative Bacilli
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1987, p. 546-550 0095-1137/87/030546-05$02.00/0 Copyright C 1987, American Society for Microbiology Vol. 25, No. 3 Evaluation of the AutoMicrobic System for Susceptibility
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationMichael T. Sweeney* and Gary E. Zurenko. Infectious Diseases Biology, Pharmacia Corporation, Kalamazoo, Michigan 49007
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2003, p. 1902 1906 Vol. 47, No. 6 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.6.1902 1906.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationIn vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms
Advance Access published April 14, 2003 Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkg238 In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and
More informationBrief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents
Journal of Antimicrobial Chemotherapy (5) 35, -5 Brief reports Heat stability of the antimicrobial activity of sixty-two antibacterial agents Walter H. Traub and Birgit Leonhard Institut fur Medizinische
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationIn Vitro Activity of Netilmicin, Gentamicin, and Amikacin
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Jan. 1977, p. 126-131 Copyright X 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. In Vitro Activity of Netilmicin, Gentamicin, and Amikacin
More informationPrevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 319-77 Volume Number (17) pp. 57-3 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/1.5/ijcmas.17..31
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationDepartment of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, 1 and Merck and Co., Inc., West Point, Pennsylvania 2
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1997, p. 881 885 Vol. 41, No. 5 0066-4804/97/$04.00 0 Copyright 1997, American Society for Microbiology Comparative In Vitro Antimicrobial Susceptibilities of
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationVersion 1.01 (01/10/2016)
CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationDetecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP)
Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationOccurrence of Extended-Spectrum Beta-Lactamases Among Blood Culture Isolates of Gram-Negative Bacteria
Original Article Vol. 21 No. 2 ESBL producers among blood culture isolates:- Kapoor L, Deb M. 53 Occurrence of Extended-Spectrum Beta-Lactamases Among Blood Culture Isolates of Gram-Negative Bacteria Lata
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationShort Report. R Boot. Keywords: Bacteria, antimicrobial susceptibility testing, quality, diagnostic laboratories, proficiency testing
Short Report Frequent major errors in antimicrobial susceptibility testing of bacterial strains distributed under the Deutsches Krebsforschungszentrum Quality Assurance Program R Boot Former Section of
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationCiprofloxacin, Enoxacin, and Ofloxacin against Aerobic and
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1988, p. 1143-1148 Vol., No. 8 0066-4804/88/081143-06$00/0 Copyright 1988, American Society for Microbiology Comparative Activities of, Amoxicillin-Clavulanic
More informationCompliance of manufacturers of AST materials and devices with EUCAST guidelines
Compliance of manufacturers of AST materials and devices with EUCAST guidelines Data are based on questionnaires to manufacturers of materials and devices for antimicrobial susceptibility testing. The
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationEvaluation of the BIOGRAM Antimicrobial Susceptibility Test System
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility
More informationSynergy of Daptomycin with Oxacillin and Other -Lactams against Methicillin-Resistant Staphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 2871 2875 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.2871 2875.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationAcinetobacter Resistance in Turkish Tertiary Care Hospitals. Zeliha KOCAK TUFAN, MD, Assoc. Prof.
Acinetobacter Resistance in Turkish Tertiary Care Hospitals Zeliha KOCAK TUFAN, MD, Assoc. Prof. Acinetobacter Problem Countries that have reported hospital outbreaks of carbapenem-resistant Acinetobacter
More informationIn Vitro Activities of Tulathromycin and Ceftiofur Combined with Other Antimicrobial Agents Using Bovine Pasteurella multocida
In Vitro Activities of Tulathromycin and Ceftiofur Combined with Other Antimicrobial Agents Using Bovine Pasteurella multocida and Mannheimia haemolytica Isolates* Michael T. Sweeney, MS Gordon W. Brumbaugh,
More informationComparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Oct. 1976, P. 592-597 Copyright 1976 American Society for Microbiology Vol. 1, No. 4 Printed in U.S.A. Comparative Activity of Netilmicin, Gentamicin, Amikacin, and
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationMulticenter Study of In Vitro Susceptibility of the Bacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1999, p. 2417 2422 Vol. 43, No. 10 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Multicenter Study of In Vitro
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationPrevalenceofAntimicrobialResistanceamongGramNegativeIsolatesinanAdultIntensiveCareUnitataTertiaryCareCenterinSaudiArabia
: K Interdisciplinary Volume 17 Issue 4 Version 1.0 Year 2017 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online ISSN: 2249-4618 & Print ISSN:
More informationChristiane Gaudreau* and Huguette Gilbert
Journal of Antimicrobial Chemotherapy (1997) 39, 707 712 JAC Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter
More informationMICHAEL J. RYBAK,* ELLIE HERSHBERGER, TABITHA MOLDOVAN, AND RICHARD G. GRUCZ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1062 1066 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Daptomycin,
More informationInfluence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 35 39 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationAntibacterial susceptibility testing
Antibiotics: Antil susceptibility testing are natural chemical substances produced by certain groups of microorganisms (fungi, ) that inhibit the growth of or kill the other that cause infection. Several
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationAminoglycoside-resistant enterococci
Aminoglycoside-resistant enterococci M. J. BASKER, B. SLOCOMBE, AND R. SUTHERLAND From Beecham Pharmaceuticals Research Division, Brockham Park, Betchworth, Surrey J. clin. Path., 1977, 30, 375-380 SUMMARY
More informationREVOLUTIONARY. MMinimum. BBiofilm EEradication Concentration. inimizing WE HAVE FOUND THE ANSWER.
REVOLUTIONARY. Are recurrent bacterial infections a frustration in your practice? WE HAVE FOUND THE ANSWER. MMinimum inimizing BBiofilm EEradication C oncentration Concentration www.becscreen.com WHY BIOFILM
More informationDetection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from a Tertiary Care Centre, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 12 (2015) pp. 578-583 http://www.ijcmas.com Original Research Article Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationEducating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges
Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association
More informationReceived 10 November 2006/Returned for modification 9 January 2007/Accepted 17 July 2007
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2007, p. 3726 3730 Vol. 51, No. 10 0066-4804/07/$08.00 0 doi:10.1128/aac.01406-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparative
More informationMulti-drug resistant Acinetobacter (MDRA) Surveillance and Control. Alison Holmes
Multi-drug resistant Acinetobacter (MDRA) Surveillance and Control Alison Holmes The organism and it s epidemiology Surveillance Control What is it? What is it? What is it? What is it? Acinetobacter :
More informationPILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996
PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More information1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient
1 Chapter 79, Self-Assessment Questions 1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient with normal renal function is: A. Trimethoprim-sulfamethoxazole B. Cefuroxime
More informationChallenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems
Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
More informationReceived 21 June 2002/Returned for modification 23 July 2002/Accepted 24 September 2002
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2002, p. 4571 4575 Vol. 40, No. 12 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.12.4571 4575.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Antibiotic Susceptibility Pattern of Pseudomonas Aeruginosa Isolated From Various Clinical
More informationavailable. and P. aeruginosa resistant to gentamicin by standardized disk testing (1) in the Microbiology Laboratory
ANTimICROBIAL AGENTh AND CHEMOTHERAPY, OCt. 1976, p. 677-681 Copyright 1976 American Society for Microbiology Vol. 10, No. 4 Printed in U.S.A. In Vitro Susceptibility of Gentamicin-Resistant Enterobacteriaceae
More informationAcinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia.
Biomedical Research 12; 23 (4): 571-575 ISSN 97-938X Scientific Publishers of India Acinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia. Nazmul MHM, Jamal
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationExtremely Drug-resistant organisms: Synergy Testing
Extremely Drug-resistant organisms: Synergy Testing Background Acinetobacter baumannii& Pseudomonas aeruginosa Emerging Gram-negative bacilli Part of the ESKAPE group of organisms 1 Enterococcus faecium
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationNational Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4606 4610 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4606 4610.2004 Copyright 2004, American Society for Microbiology. All Rights
More informationDetection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary Care Hospital in North India
Original Article Vol. 25 No. 3 Ampc β-lactamase Production in Gram-Negative Bacilli:-Chaudhary U, et al. 129 Detection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary
More information